Abarelix
- Atc Codes:L02BX01
- CAS Codes:183552-38-7
- PHARMGKB ID:183552-38-7
Table of contents
- Brand Names
- Chemistry
- Pharmacologic Category
- Therapeutic Use
- Pregnancy and Lactation Implications
- Contraindications
- Warnings and Precautions
- Adverse Reactions
- Genes that may be involved
- Drug Interactions
- Dosage
- Pharmacokinetics and Pharmacodynamics
- Special Considerations
Brand Names
Europe
Austria: Plenaxis; Germany: Plenaxis; Netherlands: Plenaxis.
Drug combinations
Chemistry
Abarelix: C~72~H~95~ClN~14~O~14~. Mw: 1416.06. N-Acetyl-3-(2-naphthyl)-D-alanyl-4-chloro-D-phenylalanyl-3-(3-pyridyl)-D-alanyl-L-seryl-N-methyl-L-tyrosyl-D-asparaginyl-L-leucyl-N^6^-isopropyl-L-lysyl-L-prolyl-D-alaninamide. CAS-183552-38-7 (1997).
Pharmacologic Category
Antineoplastic Agents; Endocrine Therapy; Gonadotropin Releasing Hormone Antagonists. (ATC-Code: L02BX01).
Mechanism of action
Therapeutic use
Palliative treatment of advanced symptomatic prostate cancer.
Pregnancy and lactiation implications
Should not be used in women.
Unlabeled use
Contraindications
Hypersensitivity to abarelix or any ingredient in the formulation. Not indicated in women or pediatric patients.
Warnings and precautions
Risk of allergic reactions. May cause fetal harm. Increases in serum AST (SGOT) or ALT (SGPT) concentrations. Prolongation of QTc interval. Risk of decreased bone mineral density following chronic therapy with GnRH antagonists and agonists.